Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
1.910
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
1.940
+0.030 (1.57%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Esperion Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Esperion Therapeutics stock have an average target of 8.75, with a low estimate of 5.00 and a high estimate of 16. The average target predicts an increase of 358.12% from the current stock price of 1.91.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 13, 2026.
Analyst Ratings
The average analyst rating for Esperion Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +161.78% | Mar 13, 2026 |
| Needham | Needham | Strong Buy Maintains $4 → $5 | Strong Buy | Maintains | $4 → $5 | +161.78% | Mar 3, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $9 | Buy | Initiates | $9 | +371.20% | Nov 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +737.70% | Sep 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +737.70% | Jun 17, 2025 |
Financial Forecast
Revenue This Year
402.08M
from 403.14M
Decreased by -0.26%
Revenue Next Year
453.60M
from 402.08M
Increased by 12.81%
EPS This Year
0.05
from -0.11
EPS Next Year
0.31
from 0.05
Increased by 517.55%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 567.3M | 572.5M | ||||||
| Avg | 402.1M | 453.6M | ||||||
| Low | 331.0M | 292.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 40.7% | 42.4% | ||||||
| Avg | -0.3% | 12.8% | ||||||
| Low | -17.9% | -27.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.59 | 0.49 | ||||||
| Avg | 0.05 | 0.31 | ||||||
| Low | -0.26 | 0.16 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 887.4% | ||||||
| Avg | - | 517.6% | ||||||
| Low | - | 219.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.